We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Implications of Aggressive in ‘PAH with comorbidities’ Therapy: What Does That Mean?
Rajan Saggar, MD
2022 ERS/ESC PAH Guidelines on Treatment
Jean M. Elwing, MD
How Should Cardiopulmonary Comorbidities Influence PH Treatment Strategy?
Richard N. Channick, MD
Richard Krasuski, MD
Essential Aspects of the New ERS/ESC Treatment Guidelines: Patients With Comorbidities
Hot Topics from the New ERS/ESC PH Guidelines: Focus on Treatment
Ioana Preston, MD
Risk Assessment in PAH
Hot Topics from the New ERS/ESC Guidelines: Definitions and Risk Assessment
Case: Using the 2022 ESC/ERS Treatment Algorithm in Older Male Patient with Cardiopulmonary Comorbidities
Implications of Aggressive Therapy in ‘PAH Without Comorbidities’
What’s the Consensus on Cardiorenal Protection for CKD in T2D?
Tessa Laubscher, MBChB, CCFP, FCFP
George L. Bakris, MD, FAHA, FASN
Mikhail Kosiborod, MD
Applying Evidence to Practice: What Can We Learn from Recent Clinical Trials of IV Iron Use in HF?
Piotr Ponikowski, MD, PhD, FESC, FHFA
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Hyperkalemia: Is It Still a Challenge in 2023?
Ileana L. Piña, MD, MPH, FAHA, FACC
Javed Butler, MD, MBA, MPH
Patrick Rossignol, MD, PhD
Sotatercept: A Novel Entity with Promising Potential for Treating PAH
Emerging PH Therapeutics: The Promise of a New Future
Sudarshan Rajagopal, MD, PhD
Oksana A. Shlobin, MD
Gene- and Nano-Therapy for PAH: Could This Be the Future?
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education